Companies › jCyte
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| jCell (famzeretcel) Human retinal progenitor cells (RPCs) | – | Phase 2 | Retinitis Pigmentosa | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06912633 | jCell (famzeretcel) | Phase 2 | Retinitis Pigmentosa | Ophthalmology | Dec 2026 |
No annotated target.
–
NovaSight Emmecell NexThera Regenerative Patch Technologies Price Vision Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.